Wellcome Trust awards Phagenesis $1.5 million for dysphagia treatment

Tuesday, May 22, 2012 10:02 AM

Phagenesis, a U.K. company focused on dysphagia (the inability to swallow), has been awarded $1.5 million from the Wellcome Trust to extend the scope of its dysphagia treatment device, from hospitals into the community.

Phagenesis’ technology is designed to treat patients who are dysphagic following a stroke. Currently, there is no generally accepted treatment for the condition and patients typically have to be fed puréed food and thickened liquids or be fed through a tube, which can severely limit their quality of life.

Phagenesis has developed the world’s first clinically-proven device to treat dysphagia in stroke patients in the first few weeks while they are hospitalised. With the help of the Wellcome Trust, Phagenesis is now developing and testing a new version of its device to treat patients suffering from long-term dysphagia.

“Our technology can make a significant difference to patients in the hospital who have this difficult-to-treat condition,” said Daniel Green, CEO of Phagenesis. “We believe this benefit can be extended more widely to people outside the hospital setting. We are delighted to have the support of the Wellcome Trust to adapt our technology and reach these patients and improve their quality of life.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs